Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells
Primary Effusion Lymphoma
Explore 19 assets in Primary Effusion Lymphoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
gene_therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01961063CT.gov Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02337985CT.gov Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Effusion Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2 | BBB |
| Etoposide | National Cancer Institute (NCI) | P2 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Adriamycin | National Cancer Institute (NCI) | P2 | BB |
| Rituximab | National Cancer Institute (NCI) | P2 | BB |
| Prednisone | National Cancer Institute (NCI) | P2 | BB |
| (+)-Vincristine | National Cancer Institute (NCI) | P2 | BB |
| Procarbazine | AIDS Malignancy Consortium | P2 | BB |
+30 more in the Primary Effusion Lymphoma cohort
Other indications for Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasmablastic Lymphoma | — | P1/2 | CCC · 54 |
| Burkitt Lymphoma | — | P1/2 | CCC · 54 |
| HIV Infectious Disease | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells in Primary Effusion Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lentivirus-vector-rhiv7-shi-tar-ccr5rz-transduced-hematopoietic-stemprogenitor-cells-primary-effusion-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →